NASDAQ · LBRX
LB Pharmaceuticals Inc Common Stock
$40.15+$0.32 (+0.8%)
LB Pharmaceuticals Inc Common Stock’s quoted price sits in the upper half of its reported 52-week range, 19.96% below the high.
Loading market information…
NASDAQ · DBVT · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
DBV Technologies S.A.’s quoted price sits in the lower half of its reported 52-week range, 60.71% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
DBV Technologies S.A.’s next earnings report is currently expected on Mar 11, 2027, with estimated earnings per share of -$0.29. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow DBV Technologies S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:31 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2025 | Jul 30, 2025 | -$1.55-638.1% vs estimate | $1.74M+129.58% vs estimate |
|---|
| Q1 2025 | Apr 30, 2025 | -$0.26-8.33% vs estimate | $800.00K+60.0% vs estimate |
|---|
| Q4 2024 | Mar 24, 2025 | -$0.26+16.2% vs estimate | $553.10K-53.55% vs estimate |
|---|
THE ANALYST VIEW
15 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$40.15+$0.32 (+0.8%)
LB Pharmaceuticals Inc Common Stock’s quoted price sits in the upper half of its reported 52-week range, 19.96% below the high.
$23.47+$0.14 (+0.6%)
Alto Neuroscience, Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.38% below the high.
$4.01-$0.03 (-0.74%)
Annexon, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.15% below the high.
$2.14+$0.04 (+1.9%)
Altimmune, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.77% below the high.
$2.67+$0.13 (+5.12%)
Larimar Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.41% below the high.
$12.74-$0.01 (-0.08%)
Amarin Corporation plc’s quoted price sits in the lower half of its reported 52-week range, 26.43% below the high.
$3.06-$0.07 (-2.24%)
Lexeo Therapeutics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 72.16% below the high.
$14.20+$0.34 (+2.45%)
Korro Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.74% below the high.
